Lumen Scientific, Inc., a clinical-stage medical technology company developing bioelectric therapies for retinal disease, today announced the first U.S. patient has been randomized in the i-SIGHT2 ...
Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits In the article that accompanies this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results